Cargando…
Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder
OBJECTIVE: Identifying the predictors of response to psychiatric and psychotherapeutic treatments may be useful for increasing treatment efficacy in pharmacoresistant depressive patients. The goal of this study was to examine the influence of dissociation, hope, personality trait, and selected demog...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063494/ https://www.ncbi.nlm.nih.gov/pubmed/27785031 http://dx.doi.org/10.2147/NDT.S117037 |
_version_ | 1782459990564405248 |
---|---|
author | Prasko, Jan Ociskova, Marie Grambal, Ales Sigmundova, Zuzana Kasalova, Petra Marackova, Marketa Holubova, Michaela Vrbova, Kristyna Latalova, Klara Slepecky, Milos |
author_facet | Prasko, Jan Ociskova, Marie Grambal, Ales Sigmundova, Zuzana Kasalova, Petra Marackova, Marketa Holubova, Michaela Vrbova, Kristyna Latalova, Klara Slepecky, Milos |
author_sort | Prasko, Jan |
collection | PubMed |
description | OBJECTIVE: Identifying the predictors of response to psychiatric and psychotherapeutic treatments may be useful for increasing treatment efficacy in pharmacoresistant depressive patients. The goal of this study was to examine the influence of dissociation, hope, personality trait, and selected demographic factors in treatment response of this group of patients. METHODS: Pharmacoresistant depressive inpatients were enrolled in the study. All patients completed Clinical Global Impression – both objective and subjective form (CGI), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI) at baseline and after 6 weeks of combined pharmacotherapy and psychotherapy (group cognitive-behavioral or group psychodynamic) treatment as an outcome measures. The Internalized Stigma of Mental Illness Scale (ISMI), Dissociative Experience Scale (DES), Adult Dispositional Hope Scale (ADHS), and Temperament and Character Inventory (TCI-R) were completed at the start of the treatment with the intention to find the predictors of treatment efficacy. RESULTS: The study included 72 patients who were hospitalized for the pharmacoresistant major depression; 63 of them completed the study. The mean scores of BDI-II, BAI, subjCGI, and objCGI significantly decreased during the treatment. BDI-II relative change statistically significantly correlated with the total ISMI score, Discrimination Experience (ISMI subscale), and Harm Avoidance (TCI-R personality trait). According to stepwise regression, the strongest factors connected to BDI-II relative change were the duration of the disorder and Discrimination Experience (domain of ISMI). ObjCGI relative change significantly correlated with the level of dissociation (DES), the total ISMI score, hope in ADHS total score, and Self-Directedness (TCI-R). According to stepwise regression, the strongest factor connected to objCGI relative change was Discrimination Experience (domain of ISMI). The existence of comorbid personality disorder did not influence the treatment response. CONCLUSION: According to the results of the present study, patients with pharmacoresistant depressive disorders, who have had more experience with discrimination because of their mental struggles, showed a poorer response to treatment. |
format | Online Article Text |
id | pubmed-5063494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50634942016-10-26 Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder Prasko, Jan Ociskova, Marie Grambal, Ales Sigmundova, Zuzana Kasalova, Petra Marackova, Marketa Holubova, Michaela Vrbova, Kristyna Latalova, Klara Slepecky, Milos Neuropsychiatr Dis Treat Original Research OBJECTIVE: Identifying the predictors of response to psychiatric and psychotherapeutic treatments may be useful for increasing treatment efficacy in pharmacoresistant depressive patients. The goal of this study was to examine the influence of dissociation, hope, personality trait, and selected demographic factors in treatment response of this group of patients. METHODS: Pharmacoresistant depressive inpatients were enrolled in the study. All patients completed Clinical Global Impression – both objective and subjective form (CGI), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI) at baseline and after 6 weeks of combined pharmacotherapy and psychotherapy (group cognitive-behavioral or group psychodynamic) treatment as an outcome measures. The Internalized Stigma of Mental Illness Scale (ISMI), Dissociative Experience Scale (DES), Adult Dispositional Hope Scale (ADHS), and Temperament and Character Inventory (TCI-R) were completed at the start of the treatment with the intention to find the predictors of treatment efficacy. RESULTS: The study included 72 patients who were hospitalized for the pharmacoresistant major depression; 63 of them completed the study. The mean scores of BDI-II, BAI, subjCGI, and objCGI significantly decreased during the treatment. BDI-II relative change statistically significantly correlated with the total ISMI score, Discrimination Experience (ISMI subscale), and Harm Avoidance (TCI-R personality trait). According to stepwise regression, the strongest factors connected to BDI-II relative change were the duration of the disorder and Discrimination Experience (domain of ISMI). ObjCGI relative change significantly correlated with the level of dissociation (DES), the total ISMI score, hope in ADHS total score, and Self-Directedness (TCI-R). According to stepwise regression, the strongest factor connected to objCGI relative change was Discrimination Experience (domain of ISMI). The existence of comorbid personality disorder did not influence the treatment response. CONCLUSION: According to the results of the present study, patients with pharmacoresistant depressive disorders, who have had more experience with discrimination because of their mental struggles, showed a poorer response to treatment. Dove Medical Press 2016-10-07 /pmc/articles/PMC5063494/ /pubmed/27785031 http://dx.doi.org/10.2147/NDT.S117037 Text en © 2016 Prasko et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Prasko, Jan Ociskova, Marie Grambal, Ales Sigmundova, Zuzana Kasalova, Petra Marackova, Marketa Holubova, Michaela Vrbova, Kristyna Latalova, Klara Slepecky, Milos Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder |
title | Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder |
title_full | Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder |
title_fullStr | Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder |
title_full_unstemmed | Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder |
title_short | Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder |
title_sort | personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063494/ https://www.ncbi.nlm.nih.gov/pubmed/27785031 http://dx.doi.org/10.2147/NDT.S117037 |
work_keys_str_mv | AT praskojan personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT ociskovamarie personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT grambalales personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT sigmundovazuzana personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT kasalovapetra personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT marackovamarketa personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT holubovamichaela personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT vrbovakristyna personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT latalovaklara personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder AT slepeckymilos personalityfeaturesdissociationselfstigmahopeandthecomplextreatmentofdepressivedisorder |